CHMP favors Briumvi for approval to treat relapsing forms of MS in EU
An arm of the European Medicines Agency favors the approval of Briumvi (ublituximab) to treat adults with active, relapsing forms of multiple sclerosis (MS) across theĀ European Union (EU). The Committee for Medicinal Products for Human Use (CHMP) opinion is based on data from twin Phase 3 trials,…